TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the completion of the Company's first shipment to France. This milestone follows a production agreement with an international medicinal cannabis organization. This strategic collaboration strengthens MediPharm's position as a trusted supplier of pharmaceutical-grade ...

LONDON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Crucial Innovations Corp., a pioneering medical cannabis company, announced the signing of a Management Services Agreement (MSA) with Cannabudgrow (Pty) Ltd (“CBG”), a licensed cultivator and exporter of medicinal cannabis based in Johannesburg, South Africa. Under the terms of the agreement, Crucial Innovations will provide CBG with comprehensive management, administrative and strategic services, including oversight of operational, logistical, and business developm ...

Seasoned finance and innovation executive brings global strategy and governance expertise to support CINV’s mission of advancing medicinal cannabis accessibility across the UK and Europe LONDON , Nov. 18, 2025 (GLOBE NEWSWIRE) -- Crucial Innovations Corp., a pioneering medical cannabis company, announced the appointment of Rory Bowen to its Board of Directors, effective immediately. Mr. Bowen is a seasoned executive, investor and strategist with extensive experience spanning finance, technology and global i ...

Core Insights - Avicanna Inc. reported Q3 2025 results, highlighting continued revenue growth and advancements in its biopharmaceutical strategy focused on cannabinoid-based products [1][2]. Financial Performance - Revenue for Q3 2025 reached $6.40 million, with a total of $18.88 million for the nine-month period ending September 30, 2025. Canadian revenue increased by 4%, marking two consecutive quarters of growth, while international revenue rose by approximately 6% compared to Q2 2025 [5]. - Gross profit was $3.15 million for Q3 2025, resulting in a gross margin of 49%, down from 57% in the prior year due to non-recurring costs and a Canada Post strike. The nine-month gross margin improved slightly to 52% from 50% in the previous period [5]. - The adjusted EBITDA loss for Q3 2025 was $0.79 million, a decrease from the same period in 2024, while the nine-month adjusted EBITDA loss was $0.61 million, showing improvement from $0.72 million in 2024 [5]. Commercial Advancements - Canadian commercial advancements led to record sales of 62,987 units in Q3 2025, a 39% increase compared to Q3 2024. The company had 52 commercial SKUs and 174 listings, representing 29% growth from Q3 2024 and 18% growth from Q2 2025 [5]. - The MyMedi.ca platform experienced growth due to medical affairs initiatives, and the B2B Medical unit saw a 113% increase in products sold. The Adult-Use business expanded into three new provinces and territories [5]. Intellectual Property and Collaborations - The United States Patent & Trademark Office issued patent No. US 12,343,315 B2 for a topical gel formulation containing cannabinoids, aimed at treating skin conditions such as acne and wrinkles [5]. - Avicanna's subsidiary completed the export of CBD-dominant cannabis flower to Switzerland, marking the first export of organic certified flower and expanding the Aureus portfolio in international markets [5]. New Product Launches - Avicanna LATAM SAS and Harrington Wellness launched the re+PLAY CBD wellness brand in the U.S., featuring products that utilize Avicanna's patented CBD formulations [6].

Core Insights - IM Cannabis Corp. is set to report its operational and financial results for Q3 2025 on November 13, 2025, before market opening [1] Company Overview - IM Cannabis Corp. is an international cannabis company focused on providing premium cannabis products to medical patients in Israel and Germany, which are among the largest medical cannabis markets [2] - The company aims for sustainable and profitable growth in its key markets, leveraging a data-driven approach and a globally sourced product supply chain [2] - IM Cannabis is committed to responsible growth and compliance with strict regulatory environments to enhance its commercial and brand power [2] Operational Ecosystem - The IMC ecosystem operates in Israel through subsidiaries that import and distribute cannabis to medical patients, utilizing proprietary data and patient insights [3] - The company manages medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel to ensure safe delivery and quality control of its products [3] - In Germany, IM Cannabis operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical cannabis patients [3]

Financial Data and Key Metrics Changes - Net revenue increased by 11% to $90 million, with record global medical cannabis revenue rising 15% and international revenue up 22% [5][16] - Consolidated adjusted gross margin improved by 700 basis points to 61%, with medical cannabis adjusted gross margin reaching 69% [5][17] - Adjusted EBITDA rose more than 52% to $15 million, significantly outpacing top-line growth [5][16] Business Line Data and Key Metrics Changes - Medical cannabis net revenue grew by 15% to $70.5 million, accounting for 78% of total net revenue [17] - Consumer cannabis net revenue decreased to $6.9 million from $10.4 million, reflecting a strategic focus on higher-margin medical cannabis [17] - Bevo's plant propagation net revenue increased by 34% to $11.6 million, driven by higher orchid sales [18] Market Data and Key Metrics Changes - Australia is the largest medical cannabis market outside Canada, with a market opportunity of AUD 1 billion [9] - In Germany, imports of medical cannabis have increased from 8 metric tons in 2018 to 72 metric tons in 2024, with expectations to double in 2025 [10] - Poland's medical cannabis market size has more than doubled from over 2 tons in 2023 to approximately 5 tons in 2025 [11] Company Strategy and Development Direction - The company focuses on global medical cannabis, emphasizing operational execution and a strong cash position without cannabis-related debt [4] - Aurora aims to strengthen its leadership in Canada, Europe, and Australia through consistent revenue generation and positive adjusted EBITDA growth [24] - The company is investing in science and technology to support patient access and physician engagement, building a foundation for long-term success [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate potential regulatory changes in Germany and Poland, citing a strong track record [10][12] - The company anticipates continued strength in adjusted gross margins and higher global medical cannabis revenue growth, leading to annual adjusted EBITDA growth [21] - Management highlighted the importance of maintaining a high-quality supply of medical cannabis to meet patient and practitioner needs [35] Other Important Information - The company ended the quarter with $142 million in cash and cash equivalents and no cannabis business debt [16][19] - Free cash flow was negative $42.3 million, reflecting expected cash outflows typical for the second quarter [20] Q&A Session Summary Question: What is a realistic goal for medical gross margins? - Management indicated that production costs are decreasing, and efficiencies in execution are contributing to higher margins [26][30] Question: What is the status of cannabis import permits in Germany? - Management confirmed that the company maintained strong relationships with regulators and was not disrupted by import limits [56][58] Question: How will proposed changes to reimbursement for medical cannabis veterans in Canada impact the business? - Management expressed disappointment over the lack of consultation and indicated that the changes could disrupt patient care [41][46] Question: What is the timeline for potential regulatory changes in Germany and Australia? - Management noted that changes in Germany could take until spring for clarity, while Australia has a more open-ended timeline [95][102]

INVESTOR PRESENTATION FY26 Q2 November 2025 Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "in ...

Core Insights - Tilray Medical has announced significant updates to its pricing programs in Canada, aimed at enhancing affordability and accessibility for medical cannabis patients [1][5] Group 1: Pricing Program Updates - The Compassionate Pricing program has increased the annual income eligibility threshold from $32,500 CAD to $65,000 CAD, allowing more patients to qualify for support [2] - Patients enrolled in the Compassionate Pricing program will continue to benefit from promotional campaigns and additional savings opportunities [2] - The 'Seniors Pricing' program has been strengthened to better support elderly patients, while dedicated programs for first responders and pediatric patients remain in place [3] Group 2: Specialized Support Programs - Tilray Medical continues to provide specialized support through the 'Warrior Wellness' program for Veterans and the 'First Responders Appreciation' program, ensuring personalized care and streamlined access to medical cannabis [4] - The company emphasizes its commitment to health equity, empowering various groups, including seniors, veterans, and families, to access medical cannabis affordably [5] Group 3: Company Overview - Tilray Medical is a leading supplier of medical cannabis, with a global portfolio of brands and products designed to meet patient needs [6] - The company has evolved from being one of the first licensed producers of medical cannabis in Canada to establishing GMP-certified production facilities in Portugal and Germany [6]

Core Points - Vireo Growth Inc. will release its financial results for the third fiscal quarter ended September 30, 2025, on November 12, 2025, before the market opens [1] - A conference call will be held on the same day at 8:30 a.m. ET to discuss the results, with dial-in options provided for interested parties [2] - A live audio webcast of the conference call will be available on the Company's Investor Relations website [3] Company Overview - Vireo Growth Inc. was founded in 2014 as a pioneering medical cannabis company, focusing on a disciplined and strategically aligned platform in the industry [4] - The Company emphasizes a strong local market focus while leveraging a national portfolio, aiming to drive value through hiring industry leaders and deploying capital effectively [4] - Vireo operates with a long-term mindset and a commitment to its customers, employees, shareholders, industry collaborators, and the communities it serves [4]

Core Viewpoint - Vireo Growth Inc. is set to release its financial results for the third fiscal quarter ended September 30, 2025, on November 12, 2025, before market opening [1] Financial Results Announcement - The financial results will be discussed in a conference call scheduled for November 12, 2025, at 8:30 a.m. ET [2] - Interested parties can join the conference call by dialing the provided toll-free and international numbers, referencing the conference ID number [2] Live Audio Webcast - A live audio webcast of the conference call will be available on the Company's Investor Relations website [3] Company Overview - Vireo Growth Inc. was founded in 2014 as a pioneering medical cannabis company, focusing on a disciplined and execution-oriented platform [4] - The company emphasizes a long-term mindset and a commitment to its customers, employees, shareholders, and communities [4]